A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction

1

Sepsis is a leading cause of death in intensive care, with high mortality rates and no effective treatments to reverse organ dysfunction.
2

Intravenous sodium ascorbate has shown promise in reversing sepsis-induced dysfunction in preclinical studies, outperforming lower doses.
3

The study aimed to determine the minimum effective dose of sodium ascorbate for optimal therapeutic benefit in sepsis.
4

High doses of sodium ascorbate significantly improved urine output and reduced vasopressor requirements in septic shock patients.
5

The experimental design included a randomized trial in sheep to evaluate the effects of varying doses of sodium ascorbate on sepsis.

Critical Care (Springer)

by Connie Pei Chen Ow, Rachel M. Peiris, Anton Trask-Marino, Sally G. Hood, Ashenafi H. Betrie, Darius J. R. Lane, Rinaldo Bellomo, Mark P. Plummer, Clive N. May, Yugeesh R. Lankadeva
December 28, 2025

1